{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:30:35Z","timestamp":1787236235023,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40121-023-00862-6","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T04:04:04Z","timestamp":1695701044000},"page":"2307-2320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04010539","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-319X","authenticated-orcid":false,"given":"Caroline R.","family":"Perry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-8261","authenticated-orcid":false,"given":"Nicole E.","family":"Scangarella-Oman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Millns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3343-4211","authenticated-orcid":false,"given":"William","family":"Flight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4825-9578","authenticated-orcid":false,"given":"Sally","family":"Gatsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4839-0266","authenticated-orcid":false,"given":"Charles","family":"Jakielaszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Janmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-8392","authenticated-orcid":false,"given":"David A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"862_CR1","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.15585\/mmwr.mm6950a6","volume":"69","author":"S St Cyr","year":"2020","unstructured":"St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, et\u00a0al. Update to CDC\u2019s treatment guidelines for gonococcal infection, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1911\u20136. https:\/\/doi.org\/10.15585\/mmwr.mm6950a6.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"862_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1071\/SH19061","volume":"16","author":"RD Kirkcaldy","year":"2019","unstructured":"Kirkcaldy RD, Weston E, Segurado AC, Hughes G. Epidemiology of gonorrhoea: a global perspective. Sex Health. 2019;16:401\u201311. https:\/\/doi.org\/10.1071\/SH19061.","journal-title":"Sex Health"},{"key":"862_CR3","unstructured":"Centers for Disease Control and Prevention. Sexually transmitted disease surveillance. Available at: https:\/\/www.cdc.gov\/std\/stats18\/STDSurveillance2018-full-report.pdf. Accessed May 2023."},{"key":"862_CR4","unstructured":"World Health Organization. Gonorrhoea: latest antimicrobial global surveillance results and guidance for vaccine development published. Available at: https:\/\/www.who.int\/news\/item\/22-11-2021-gonorrhoea-antimicrobial-resistance-results-and-guidance-vaccine-development. Accessed May 2023."},{"key":"862_CR5","doi-asserted-by":"publisher","first-page":"2200057","DOI":"10.2807\/1560-7917.ES.2022.27.40.2200057","volume":"27","author":"R Merrick","year":"2022","unstructured":"Merrick R, Cole M, Pitt R, Enayat Q, Ivanov Z, Day M, et\u00a0al. Antimicrobial-resistant gonorrhoea: the national public health response, England, 2013 to 2020. Euro Surveill. 2022;27:2200057. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.40.2200057.","journal-title":"Euro Surveill"},{"key":"862_CR6","doi-asserted-by":"publisher","first-page":"102401","DOI":"10.1016\/j.tmaid.2022.102401","volume":"49","author":"MLM Vicente-de-la-Cruz","year":"2022","unstructured":"Vicente-de-la-Cruz MLM, Giesen C, D\u00edaz-Men\u00e9ndez M. International travels and transmission of multidrug resistant Neisseria gonorrhoeae in Europe: a systematic review. Travel Med Infect Dis. 2022;49:102401. https:\/\/doi.org\/10.1016\/j.tmaid.2022.102401.","journal-title":"Travel Med Infect Dis"},{"key":"862_CR7","unstructured":"World Health Organization. Multi-drug resistant gonorrhoea. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/multi-drug-resistant-gonorrhoea. Accessed May 2023."},{"key":"862_CR8","doi-asserted-by":"publisher","first-page":"e0395222","DOI":"10.1128\/spectrum.03952-22","volume":"10","author":"F Yang","year":"2022","unstructured":"Yang F, Liu J, Gu Y, Jiao R, Yan J, Gao S, et\u00a0al. Antimicrobial activity of auranofin, cannabidivarin, and tolfenamic acid against multidrug-resistant Neisseria gonorrhoeae. Microbiol Spectr. 2022;10:e0395222. https:\/\/doi.org\/10.1128\/spectrum.03952-22.","journal-title":"Microbiol Spectr."},{"key":"862_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/bs.ampbs.2022.01.002","volume":"80","author":"LR Green","year":"2022","unstructured":"Green LR, Cole J, Parga EFD, Shaw JG. Neisseria gonorrhoeae physiology and pathogenesis. Adv Microb Physiol. 2022;80:35\u201383. https:\/\/doi.org\/10.1016\/bs.ampbs.2022.01.002.","journal-title":"Adv Microb Physiol"},{"key":"862_CR10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/jac\/dkaa559","volume":"76","author":"H Fifer","year":"2021","unstructured":"Fifer H, Livermore DM, Uthayakumaran T, Woodford N, Cole MJ. What\u2019s left in the cupboard? Older antimicrobials for treating gonorrhoea. J Antimicrob Chemother. 2021;76:1215\u201320. https:\/\/doi.org\/10.1093\/jac\/dkaa559.","journal-title":"J Antimicrob Chemother"},{"key":"862_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.14745\/ccdr.v45i23a02","volume":"45","author":"M Bodie","year":"2019","unstructured":"Bodie M, Gale-Rowe M, Alexandre S, Auguste U, Tomas K, Martin I. Addressing the rising rates of gonorrhea and drug-resistant gonorrhea: There is no time like the present. Can Commun Dis Rep. 2019;45:54\u201362. https:\/\/doi.org\/10.14745\/ccdr.v45i23a02.","journal-title":"Can Commun Dis Rep"},{"key":"862_CR12","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Available at: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed May 2023."},{"key":"862_CR13","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","volume":"2","author":"M Unemo","year":"2021","unstructured":"Unemo M, Lahra MM, Escher M, Eremin S, Cole MJ, Galarza P, et\u00a0al. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017\u201318: a retrospective observational study. Lancet Microbe. 2021;2:e627\u201336. https:\/\/doi.org\/10.1016\/S2666-5247(21)00171-3.","journal-title":"Lancet Microbe"},{"key":"862_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.idc.2023.02.004","volume":"37","author":"EC Ewers","year":"2023","unstructured":"Ewers EC, Curtin JM, Ganesan A. Challenges in managing gonorrhea and new advances in prevention. Infect Dis Clin North Am. 2023;37:223\u201343. https:\/\/doi.org\/10.1016\/j.idc.2023.02.004.","journal-title":"Infect Dis Clin North Am"},{"key":"862_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"KA Workowski","year":"2021","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et\u00a0al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70:1\u2013187. https:\/\/doi.org\/10.15585\/mmwr.rr7004a1.","journal-title":"MMWR Recomm Rep"},{"key":"862_CR16","doi-asserted-by":"publisher","first-page":"2200803","DOI":"10.2807\/1560-7917.Es.2022.27.46.2200803","volume":"27","author":"M Day","year":"2022","unstructured":"Day M, Pitt R, Mody N, Saunders J, Rai R, Nori A, et\u00a0al. Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022. Euro Surveill. 2022;27:2200803. https:\/\/doi.org\/10.2807\/1560-7917.Es.2022.27.46.2200803.","journal-title":"Euro Surveill"},{"key":"862_CR17","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jac\/dkaa526","volume":"76","author":"J Yan","year":"2021","unstructured":"Yan J, Chen Y, Yang F, Ling X, Jiang S, Zhao F, et\u00a0al. High percentage of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone among isolates from a single hospital in Hangzhou, China. J Antimicrob Chemother. 2021;76:936\u20139. https:\/\/doi.org\/10.1093\/jac\/dkaa526.","journal-title":"J Antimicrob Chemother"},{"key":"862_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1128\/cmr.00010-14","volume":"27","author":"M Unemo","year":"2014","unstructured":"Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27:587\u2013613. https:\/\/doi.org\/10.1128\/cmr.00010-14.","journal-title":"Clin Microbiol Rev"},{"key":"862_CR19","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2022.532","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Shi S, Dai Y, Jiang M, Jiang P, Xu D, et\u00a0al. Surveillance of the antimicrobial susceptibility and molecular characteristics of Neisseria gonorrhoeae isolates collected in Changsha China from 2016 to 2021. Jpn J Infect Dis. 2022. https:\/\/doi.org\/10.7883\/yoken.JJID.2022.532.","journal-title":"Jpn J Infect Dis"},{"key":"862_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","volume":"5","author":"EG Gibson","year":"2019","unstructured":"Gibson EG, Bax B, Chan PF, Osheroff N. Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase. ACS Infect Dis. 2019;5:570\u201381. https:\/\/doi.org\/10.1021\/acsinfecdis.8b00315.","journal-title":"ACS Infect Dis"},{"key":"862_CR21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nature09197","volume":"466","author":"BD Bax","year":"2010","unstructured":"Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, et\u00a0al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature. 2010;466:935\u201340. https:\/\/doi.org\/10.1038\/nature09197.","journal-title":"Nature"},{"key":"862_CR22","unstructured":"Oviatt A, Huang J, Ingraham K, Chan PF, Osheroff N. Biochemical and genetic evidence that gepotidacin demonstrates well-balanced dual targeting against DNA gyrase and topoisomerase IV in Escherichia coli. ECCMID 2022; 2022 23\u201326 April; Lisbon, Portugal."},{"key":"862_CR23","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3390\/ijms24021634","volume":"24","author":"H Morgan","year":"2023","unstructured":"Morgan H, Lipka-Lloyd M, Warren AJ, Hughes N, Holmes J, Burton NP, et\u00a0al. A 2.8 \u00c5 structure of Zoliflodacin in a DNA cleavage complex with Staphylococcus aureus DNA gyrase. Int J Mol Sci. 2023;24:1634. https:\/\/doi.org\/10.3390\/ijms24021634.","journal-title":"Int J Mol Sci"},{"key":"862_CR24","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1128\/aac.02820-15","volume":"60","author":"DJ Biedenbach","year":"2016","unstructured":"Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, et\u00a0al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother. 2016;60:1918\u201323. https:\/\/doi.org\/10.1128\/aac.02820-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"862_CR25","unstructured":"Mushtaq S, Vickers A, Sadouki Z, Cole M, Fifer H, DaNascimento V, et\u00a0al. In vitro activities of gepotidacin, a novel triazaacenaphthylene topoisomerase IV and DNA gyrase inhibitor, against Gram-negative bacteria and Staphylococcus saprophyticus. ECCMID 2019; 2019; Amsterdam, The Netherlands."},{"key":"862_CR26","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/jac\/dky162","volume":"73","author":"S Jacobsson","year":"2018","unstructured":"Jacobsson S, Golparian D, Scangarella-Oman N, Unemo M. In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae. J Antimicrob Chemother. 2018;73:2072\u20137. https:\/\/doi.org\/10.1093\/jac\/dky162.","journal-title":"J Antimicrob Chemother"},{"key":"862_CR27","doi-asserted-by":"publisher","first-page":"e02095","DOI":"10.1128\/aac.02095-16","volume":"61","author":"W O\u2019Riordan","year":"2017","unstructured":"O\u2019Riordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton T, et\u00a0al. Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed Gram-positive acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2017;61:e02095-16. https:\/\/doi.org\/10.1128\/aac.02095-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"862_CR28","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/cid\/ciy145","volume":"67","author":"SN Taylor","year":"2018","unstructured":"Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, et\u00a0al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis. 2018;67:504\u201312. https:\/\/doi.org\/10.1093\/cid\/ciy145.","journal-title":"Clin Infect Dis"},{"key":"862_CR29","doi-asserted-by":"publisher","first-page":"e00199","DOI":"10.1128\/aac.00199-20","volume":"64","author":"JS Overcash","year":"2020","unstructured":"Overcash JS, Tiffany CA, Scangarella-Oman NE, Perry CR, Tao Y, Hossain M, et\u00a0al. Phase 2a pharmacokinetic, safety, and exploratory efficacy evaluation of oral gepotidacin (GSK2140944) in female participants with uncomplicated urinary tract infection (acute uncomplicated cystitis). Antimicrob Agents Chemother. 2020;64:e00199-e220. https:\/\/doi.org\/10.1128\/aac.00199-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"862_CR30","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1007\/s40121-022-00706-9","volume":"11","author":"C Perry","year":"2022","unstructured":"Perry C, Hossain M, Powell M, Raychaudhuri A, Scangarella-Oman N, Tiffany C, et\u00a0al. Design of two phase III, randomized, multicenter studies comparing gepotidacin with nitrofurantoin for the treatment of uncomplicated urinary tract infection in female participants. Infect Dis Ther. 2022;11:2297\u2013310. https:\/\/doi.org\/10.1007\/s40121-022-00706-9.","journal-title":"Infect Dis Ther"},{"key":"862_CR31","doi-asserted-by":"publisher","first-page":"e01221","DOI":"10.1128\/AAC.01221-18","volume":"62","author":"NE Scangarella-Oman","year":"2018","unstructured":"Scangarella-Oman NE, Hossain M, Dixon PB, Ingraham K, Min S, Tiffany CA, et\u00a0al. Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2018;62:e01221-18. https:\/\/doi.org\/10.1128\/AAC.01221-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"862_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/sextrans-2022-055518","volume":"99","author":"NE Scangarella-Oman","year":"2022","unstructured":"Scangarella-Oman NE, Hossain M, Perry CR, Tiffany C, Powell M, Swift B, et\u00a0al. Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea. Sex Transm Infect. 2022;99:64\u20139. https:\/\/doi.org\/10.1136\/sextrans-2022-055518.","journal-title":"Sex Transm Infect"},{"key":"862_CR33","doi-asserted-by":"publisher","first-page":"e00521","DOI":"10.1128\/AAC.00521-20","volume":"64","author":"BD VanScoy","year":"2020","unstructured":"VanScoy BD, Scangarella-Oman NE, Fikes S, Min S, Huang J, Ingraham K, et\u00a0al. Relationship between gepotidacin exposure and prevention of on-therapy resistance amplification in a Neisseria gonorrhoeae hollow-fiber in vitro infection model. Antimicrobial Agents Chemother. 2020;64:e00521\u201320. https:\/\/doi.org\/10.1128\/AAC.00521-20.","journal-title":"Antimicrobial Agents Chemother"},{"key":"862_CR34","doi-asserted-by":"publisher","first-page":"e0126321","DOI":"10.1128\/AAC.01263-21","volume":"66","author":"A Barth","year":"2022","unstructured":"Barth A, Hossain M, Brimhall DB, Perry CR, Tiffany CA, Xu S, et\u00a0al. Pharmacokinetics of oral formulations of gepotidacin (GSK2140944), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, in healthy adult and adolescent participants. Antimicrob Agents Chemother. 2022;66:e0126321. https:\/\/doi.org\/10.1128\/AAC.01263-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"862_CR35","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/cpdd.913","volume":"10","author":"M Hossain","year":"2021","unstructured":"Hossain M, Tiffany C, Tao Y, Barth A, Marbury TC, Preston RA, et\u00a0al. Pharmacokinetics of gepotidacin in subjects with normal hepatic function and hepatic impairment. Clin Pharmacol Drug Dev. 2021;10:588\u201397. https:\/\/doi.org\/10.1002\/cpdd.913.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"862_CR36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/cpdd.807","volume":"9","author":"M Hossain","year":"2020","unstructured":"Hossain M, Tiffany C, Raychaudhuri A, Nguyen D, Tai G, Alcorn H Jr, et\u00a0al. Pharmacokinetics of gepotidacin in renal impairment. Clin Pharmacol Drug Dev. 2020;9:560\u201372. https:\/\/doi.org\/10.1002\/cpdd.807.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"862_CR37","doi-asserted-by":"publisher","first-page":"e02385","DOI":"10.1128\/AAC.02385-16","volume":"61","author":"M Hossain","year":"2017","unstructured":"Hossain M, Zhou M, Tiffany C, Dumont E, Darpo B. A phase I, randomized, double-blinded, placebo- and moxifloxacin-controlled, four-period crossover study to evaluate the effect of gepotidacin on cardiac conduction as assessed by 12-lead electrocardiogram in healthy volunteers. Antimicrob Agents Chemother. 2017;61:e02385\u201316. https:\/\/doi.org\/10.1128\/AAC.02385-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"862_CR38","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3109\/00498254.2015.1112933","volume":"46","author":"K Negash","year":"2016","unstructured":"Negash K, Andonian C, Felgate C, Chen C, Goljer I, Squillaci B, et\u00a0al. The metabolism and disposition of GSK2140944 in healthy human subjects. Xenobiotica. 2016;46:683\u2013702. https:\/\/doi.org\/10.3109\/00498254.2015.1112933.","journal-title":"Xenobiotica"},{"key":"862_CR39","doi-asserted-by":"crossref","unstructured":"Wagenlehner F, Perry CR, Hooton TM, Scangarella-Oman NE, Millns H, Feng H, et\u00a0al. Efficacy and safety of oral gepotidacin in the treatment of uncomplicated urinary tract infection: results of two randomised, multicentre phase 3 trials (EAGLE-2 and EAGLE-3). ECCMID; 2023; Copenhagen, Denmark.","DOI":"10.1093\/jacamr\/dlad077.035"},{"key":"862_CR40","unstructured":"Tiffany CA, Hossain M, McDonald M, Dumont EF. Effect of food on safety, tolerability and pharmacokinetics in healthy volunteers > 65 years following multiple doses of GSK2140944, a novel bacterial topoisomerase inhibitor. In: 55th Interscience conference of antimicrobial agents and chemotherapy; 2015. September 17\u201321 San Diego, CA, USA."},{"key":"862_CR41","unstructured":"Food and Drug Administration. Uncomplicated gonorrhea: developing drugs for treatment. Guidance for industry. 2015. https:\/\/www.fda.gov\/files\/drugs\/published\/Uncomplicated-Gonorrhea--Developing-Drugs-for-Treatment.pdf."},{"key":"862_CR42","unstructured":"UK Health Security Agency. Managing incidents of ceftriaxone-resistant Neisseria gonorrhoeae in England. https:\/\/www.gov.uk\/government\/publications\/ceftriaxone-resistant-neisseria-gonorrhoeae-incident-management\/managing-incidents-of-ceftriaxone-resistant-neisseria-gonorrhoeae-in-england Accessed May 2023."},{"key":"862_CR43","unstructured":"US Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. [July 2017]. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf. Accessed May 2023."},{"key":"862_CR44","unstructured":"Food and Drug Administration. Non-inferiority clinical trials to establishing effectiveness. https:\/\/www.fda.gov\/media\/78504\/download. Accessed May 2023."},{"key":"862_CR45","unstructured":"Base SAS\u00ae 9.4 Procedures Guide: Statistical Procedures, Second Edition. https:\/\/support.sas.com\/documentation\/cdl\/en\/procstat\/66703\/PDF\/default\/procstat.pdf. pp 177\u20138."},{"key":"862_CR46","doi-asserted-by":"publisher","first-page":"e0039922","DOI":"10.1128\/jcm.00399-22","volume":"60","author":"LA Barbee","year":"2022","unstructured":"Barbee LA, Soge OO, Khosropour CM, LeClair A, Golden MR. Time to clearance of Neisseria gonorrhoeae RNA at the pharynx following treatment. J Clin Microbiol. 2022;60:e0039922. https:\/\/doi.org\/10.1128\/jcm.00399-22.","journal-title":"J Clin Microbiol"},{"key":"862_CR47","unstructured":"Centers for Disease Control and Prevention. Gonorrhea treatment and care. Available at: https:\/\/www.cdc.gov\/std\/gonorrhea\/treatment.htm. Accessed May 2023."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00862-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00862-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00862-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T14:26:45Z","timestamp":1697552805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00862-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00862-6","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Caroline R. Perry, Nicole E. Scangarella-Oman, Helen Millns, William Flight, Sally Gatsi, Charles Jakielaszek, and Salim Janmohamed are employees of, and shareholders in, GSK. David A. Lewis is employed by Western Sydney Local Health District and has no disclosures to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies are conducted in accordance with the protocols and consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, International Council on Harmonization Good Clinical Practice Guidelines, and applicable laws and regulations. Protocol and amendments, informed consent form\/adolescent assent form\/eConsent (if applicable), investigator\u2019s brochure, and other relevant documents (e.g., advertisements) were submitted to an institutional review board\/independent ethics committee (IRB\/IEC) by the investigator and reviewed and approved by the IRB\/IEC before the study was initiated. The master IRB was Advarra Institutional Review Board (Columbia, MD, USA), while study sites outside the USA used their appropriate local IRB\/IEC. Adolescent patients will only be enrolled at study sites where investigators have experience in this population and if allowed per the study site\u2019s institutional ethics committees and local country\/national regulatory guidelines; enrollment will be contingent upon such approvals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}